AMRX(Amneal Pharmaceuticals, Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $2.09B | $2.21B | $2.39B | $2.79B | $3.02B |
| 毛利润 | $768.97M | $784.71M | $820.57M | $1.02B | $1.11B |
| 营业利润 | $152.72M | −$94.93M | $204.37M | $249.33M | $394.10M |
| 净利润 | $13.16M | −$270.58M | −$83.99M | −$116.89M | $72.06M |
| 经营现金流 | $241.82M | $65.10M | $345.58M | $295.10M | $339.99M |
| 自由现金流 | $194.09M | $18.69M | $302.36M | $243.18M | $269.93M |
| 摊薄每股收益 | $0.07 | $-0.86 | $-0.48 | $-0.38 | $0.22 |